AIM Vaccine Co. Ltd. Receives Approval to Begin Clinical Trials for 20-Valent Pneumococcal Vaccine
I'm PortAI, I can summarize articles.
AIM Vaccine Co. Ltd. has received approval from the National Medical Products Administration to start clinical trials for its 20-valent pneumococcal polysaccharide conjugate vaccine. This new vaccine builds on the earlier 13-valent version. Currently, only Pfizer’s Prevenar 20 is approved for marketing abroad, with no similar vaccine approved in China. This approval signifies an expansion of AIM's R&D pipeline in the pneumococcal vaccine sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments